VJHemOnc is committed to improving our service to you

MPN Advances Day 2019 | Myelofibrosis management: ruxolitinib, fedratinib, transplant

VJHemOnc is committed to improving our service to you

Ruben Mesa

Ruben Mesa, MD, FACP, Mays Cancer Center, UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX, provides an update on the management of myelofibrosis in 2019. He highlights fedratinib, which was recently approved in the US and may be making its way to Europe, as well as stem cell transplantation. This interview took place at the Myeloproliferative Neoplasms Advances Day 2019 in London, UK.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter